What it's for (Indications)
- Idarubicin is an anthracycline antineoplastic agent primarily indicated for the treatment of acute myeloid leukemia (AML) in adults.
- It is commonly used as a component of induction therapy regimens for newly diagnosed AML, often in combination with other chemotherapeutic agents, such as cytarabine.
- The goal of idarubicin-containing regimens in AML is to induce remission by effectively targeting and eliminating rapidly proliferating leukemic blast cells.
- Its use in specific AML subtypes or refractory disease may also be considered based on clinical evidence and patient characteristics, always within established treatment protocols.
- This treatment strategy aims to reduce the burden of malignant cells, facilitate hematopoietic recovery, and ultimately improve patient survival outcomes in this aggressive hematologic malignancy.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Idarubicin is administered intravenously, typically as a short infusion (e.g., 10-15 minutes), to minimize the risk of extravasation. The precise dosage and schedule depend heavily on the specific treatment protocol, patient's overall condition, and whether it's used as monotherapy or in combination regimens. For example, in adult induction therapy for AML, a common regimen involves idarubicin 12 mg/m²/day given intravenously for 3 consecutive days, in combination with cytarabine. Dosage adjustments are crucial in patients with impaired hepatic or renal function to prevent increased toxicity; specifically, dose reductions are recommended for elevated bilirubin or creatinine levels. Cumulative lifetime doses must also be carefully monitored to mitigate the risk of cardiotoxicity, a significant concern with anthracyclines. Close monitoring of blood counts and organ function throughout the treatment course is imperative to guide appropriate dosing and manage potential toxicities. |
Safety & Warnings
Common Side Effects
- Idarubicin, like other anthracyclines, is associated with a wide spectrum of adverse effects due to its potent cytotoxic action.
- Profound and prolonged myelosuppression (neutropenia, thrombocytopenia, and anemia) is nearly universal and dose-limiting, leading to increased risk of severe infections and hemorrhagic complications.
- Gastrointestinal toxicities are very common, including severe nausea, vomiting, mucositis (stomatitis), esophagitis, diarrhea, and abdominal pain.
- Alopecia (hair loss) is also frequently observed.
- Serious but less common adverse effects include cardiotoxicity, which can manifest as dose-dependent, irreversible congestive heart failure, and is a major long-term concern.
- Extravasation at the injection site can lead to severe local tissue necrosis.
- Other potential effects include fever, fatigue, transient elevations in liver enzymes, hyperuricemia (due to tumor lysis syndrome), skin rash, and the development of secondary malignancies, particularly therapy-related acute myeloid leukemia or myelodysplastic syndrome.
- Patients often experience a harmless red discoloration of urine due to the drug's metabolites.
Serious Warnings
- Black Box Warning: Idarubicin carries several prominent Black Box Warnings due to its severe and potentially life-threatening toxicities, which necessitate careful patient selection, monitoring, and management. **1. Severe Myelosuppression:** Idarubicin causes profound and prolonged myelosuppression, including severe neutropenia, thrombocytopenia, and anemia. This can lead to life-threatening infections, sepsis, and hemorrhagic complications. Frequent monitoring of complete blood counts is mandatory, and supportive care, including transfusions and growth factor support, may be required. **2. Cardiotoxicity:** Idarubicin poses a significant risk of severe, irreversible, and potentially fatal congestive heart failure. This risk is dose-dependent and cumulative. Cardiac function, particularly left ventricular ejection fraction (LVEF), must be carefully assessed prior to and throughout treatment. Patients with pre-existing cardiac disease or those who have received prior cardiotoxic agents are at increased risk. The cumulative lifetime dose must be meticulously tracked to minimize this risk. **3. Secondary Malignancies:** Treatment with idarubicin, especially in combination with other antineoplastic agents, increases the risk of developing secondary therapy-related acute myeloid leukemia (t-AML) and myelodysplastic syndromes (t-MDS). These secondary malignancies can occur several years after treatment. **4. Extravasation:** Idarubicin is a vesicant, and extravasation during intravenous administration can lead to severe local tissue necrosis, blistering, pain, and ulceration, often requiring surgical debridement or skin grafting. Proper administration technique and immediate management of extravasation are critical to prevent these severe consequences.
- Beyond the specific black box warnings, idarubicin carries several other critical safety warnings that necessitate careful clinical management.
- Patients must be closely monitored for profound and prolonged myelosuppression, which can lead to life-threatening infections and hemorrhage; complete blood counts should be performed frequently.
- Cardiotoxicity, including delayed and potentially irreversible congestive heart failure, is a significant cumulative dose-dependent risk requiring regular assessment of cardiac function (e.
- g.
- , LVEF by ECHO or MUGA scan) before and during treatment.
- The risk of developing secondary malignancies, such as therapy-related acute myeloid leukemia (t-AML) and myelodysplastic syndromes (t-MDS), is elevated with idarubicin exposure, often with a latency period.
- Extravasation during intravenous administration can cause severe local tissue necrosis; careful administration technique and prompt management protocols for extravasation are essential.
- Hepatic and renal function must be assessed prior to and during treatment, as dose adjustments are necessary in impaired organ function to prevent increased systemic exposure and toxicity.
- Tumor lysis syndrome can occur, especially in patients with a high tumor burden, requiring prophylactic measures and close metabolic monitoring.
- Idarubicin is teratogenic and embryotoxic; therefore, effective contraception must be used during treatment and for a period thereafter by both male and female patients.
- It is also advised against breastfeeding due to potential drug excretion into breast milk.
- Live attenuated vaccines are contraindicated during treatment due to the immunocompromised state.
How it Works (Mechanism of Action)
Idarubicin is an anthracycline topoisomerase II inhibitor that exerts its antineoplastic effects through several interconnected mechanisms. Its primary mode of action involves intercalation into the DNA helix, specifically between base pairs, which distorts the DNA structure and unwinds the double helix. This intercalation hinders DNA replication and transcription, thereby inhibiting nucleic acid synthesis. Concurrently, idarubicin acts as an inhibitor of topoisomerase II, an enzyme crucial for maintaining DNA topology by regulating supercoiling and uncoiling during replication and transcription. By inhibiting topoisomerase II, idarubicin prevents the re-ligation of DNA strands, leading to persistent DNA double-strand breaks and ultimately triggering apoptosis (programmed cell death) in cancer cells. Furthermore, idarubicin is capable of generating free radicals, particularly reactive oxygen species, which can cause oxidative damage to DNA, proteins, and lipids within the cell membrane, contributing to its cytotoxic effects. While it can affect cells at various stages, its impact is most pronounced on rapidly dividing cells, making it effective against proliferative malignancies like acute myeloid leukemia.
Commercial Brands (Alternatives)
No other brands found for this formula.